The threshold debate in Norway
In 2025, 79% of completed health technology assessments in Norway were evaluated as positive.
Pricing and Market Access
Trump administration announces MFN drug pricing deal with Pfizer
Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights
AstraZeneca launches DTC platform amid US pricing pressures
VPAG stalemate – how can the UK pharma market be rescued?
Morocco’s sweeping pharmaceutical pricing reform
Trade-offs abound as big pharma makes direct-to-consumer transition
Lilly first to opt for confidential reimbursement price in Germany
